Stockscreener 앱 받기
4.12
3.51%
-0.15
시간 외 거래:
4.12
전일 마감가:
$4.27
열려 있는:
$4.4
하루 거래량:
188.98K
Relative Volume:
2.62
시가총액:
$13.22M
수익:
-
순이익/손실:
$-45.52M
주가수익비율:
-0.4236
EPS:
-9.7265
순현금흐름:
$-31.51M
1주 성능:
-22.99%
1개월 성능:
-52.97%
6개월 성능:
-36.71%
1년 성능:
+1,119%
1일 변동 폭
$4.01
$4.45
1주일 범위
$4.01
$5.4775
52주 변동 폭
$0.257
$20.00
Passage Bio Inc Stock (PASG) Company Profile
명칭
Passage Bio Inc
전화
(267) 866-0312
주소
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Compare PASG vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
4.12 | 13.70M | 0 | -45.52M | -31.51M | -9.7265 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-21 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2026-04-21 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2026-04-21 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2026-03-31 | 개시 | Oppenheimer | Outperform |
| 2026-02-10 | 재개 | Chardan Capital Markets | Buy |
| 2024-11-29 | 재개 | Wedbush | Outperform |
| 2024-09-03 | 개시 | Rodman & Renshaw | Buy |
| 2022-03-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-01-19 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-07-01 | 개시 | Raymond James | Outperform |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-03-04 | 업그레이드 | Goldman | Neutral → Buy |
| 2021-02-04 | 개시 | Guggenheim | Buy |
| 2021-01-25 | 개시 | Wedbush | Outperform |
| 2021-01-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-12-11 | 개시 | Citigroup | Neutral |
| 2020-08-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-06-25 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-03-25 | 개시 | Chardan Capital Markets | Buy |
| 2020-03-24 | 개시 | Cowen | Outperform |
| 2020-03-24 | 개시 | Goldman | Buy |
| 2020-03-24 | 개시 | JP Morgan | Overweight |
모두보기
Passage Bio Inc 주식(PASG)의 최신 뉴스
symbol__ Stock Quote Price and Forecast - CNN
Layoff Tracker: Passage axes 75% of staff, explores strategic alternatives - BioSpace
Passage Bio Announces Major Workforce Reduction and Restructuring - TipRanks
Passage Bio (NASDAQ: PASG) slashes workforce by 75% in 2026 restructuring - Stock Titan
Passage Bio Reports Trial Data, Reviews Strategic Options - MyChesCo
Chardan Capital Maintains Passage Bio (PASG) Buy Recommendation - MSN
Canaccord Genuity Remains a Buy on Passage Bio (PASG) - The Globe and Mail
PASG Maintains Rating by Oppenheimer -- Price Target Lowered to $15 - GuruFocus
PASG Downgraded by Chardan Capital -- Price Target Lowered to $7 - GuruFocus
Passage Bio (PASG) Downgraded by Wedbush Analyst - GuruFocus
PASG Downgraded by TD Cowen -- Rating Changed to Hold - GuruFocus
Passage Bio Faces Tougher FDA Road After Trial Shift, Wedbush Says - marketscreener.com
PASG Downgraded by Wedbush -- Price Target Lowered to $8.00 - GuruFocus
Passage Bio Seen as Undervalued Despite FDA Setback, Oppenheimer Says - marketscreener.com
Passage Bio downgraded to Neutral from Buy at Chardan - TipRanks
This Mohawk Industries Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Tuesday - Benzinga
Passage Bio stock rating cut to Hold by TD Cowen on FDA trial news - Investing.com South Africa
Oppenheimer Adjusts Price Target on Passage Bio to $15 From $30, Maintains Outperform Rating - marketscreener.com
Wedbush Downgrades Passage Bio to Neutral From Outperform, Cuts Price Target to $8 From $32 - marketscreener.com
Oppenheimer cuts Passage Bio stock price target on regulatory setback - Investing.com
Oppenheimer cuts Passage Bio stock price target on regulatory setback By Investing.com - Investing.com Australia
Passage Bio Announces PBFT02 Data and Strategic Review - The Globe and Mail
Chardan Downgrades Passage Bio to Neutral From Buy, Cuts Price Target to $7 From $21 - marketscreener.com
Chardan downgrades Passage Bio stock rating on strategic review By Investing.com - Investing.com South Africa
Chardan downgrades Passage Bio stock rating on strategic review - Investing.com
Passage Bio to Present at H.C. Wainwright Global Investment Conference - MSN
Wedbush Maintains Passage Bio(PASG.US) With Buy Rating, Maintains Target Price $32 - Moomoo
New Developments for Passage Bio (PASG) in Frontotemporal Dement - GuruFocus
Is Passage Bio (PASG) stock safe today (Underperforming) 2026-04-20Viral Momentum Stocks - Xã Thanh Hà
Lucid downgrades Passage Bio stock rating on funding concerns By Investing.com - Investing.com South Africa
Lucid downgrades Passage Bio stock rating on funding concerns - Investing.com
Passage Bio Starts Strategic Review After FDA Doesn't Support Single-Arm Trial - Moomoo
Passage Bio Reports Positive Interim Data for PBFT02 in FTD-GRN, Initiates Strategic Review After FDA Guidance 1 - Minichart
Passage Bio reports biomarker improvements in FTD trial - Investing.com
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Passage Bio reports biomarker improvements in FTD trial By Investing.com - Investing.com Canada
Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates - The Manila Times
Gene therapy company Passage Bio, Inc. recently disclosed two major decisions: the official appointment of Wedbush Pacgrow as its financial advisor, and the commencement of a comprehensive evaluation of strategic alternatives. - Bitget
Strategic review at Passage Bio (NASDAQ: PASG) after FDA trial guidance - Stock Titan
Leading Companies Fueling Innovation and Growth in the GM1 Gangliosidosis Market - openPR.com
Short Squeeze: What is the earnings history of Passage Bio IncTrade Entry Report & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
PMN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Passage Bio Inc (PASG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.77%
0.25%
자본화:
|
볼륨(24시간):